Source disclosure: March 05, 2026, 12:00 JST
Published by Pulse News Wire: March 05, 2026, 12:08 JST
ONO PHARMACEUTICAL CO.,LTD. [4528.T]
TOKYO, Mar 05 (Pulse News Wire) – ONO Pharmaceutical CO.,LTD. (4528.T) announced today that its board of directors held on March 05, 2026, approved the introduction of a long-term stock incentive plan for employees of its U.S.
Subsidiary, Deciphera Pharmaceuticals, Inc. The initiative aims to enhance employee engagement and align their interests with the company's growth objectives. Under the Employee Stock Ownership Plan (ESOP) trust, eligible Deciphera employees will receive shares based on predefined criteria. The ESOP trust will purchase up to ¥20.454 billion worth of Ono Pharmaceutical’s shares, totaling 8,398,300 shares, which will be distributed according to the established share issuance regulations. This move is expected to boost employee motivation and improve corporate value through increased participation in decision-making processes.
Additionally, the company resolved to dispose of 8,398,300 self-held shares currently valued at ¥20.454 billion to fund the ESOP trust. Detailed information regarding this transaction can be found in the separate disclosure dated March 05, 2026, concerning the allotment of own shares to third parties. The ESOP trust structure includes provisions for dividend payments on the acquired shares and mechanisms for exercising voting rights in accordance with beneficiary directives. Upon the conclusion of the trust period ending March 31, 2029, residual shares will either continue to be utilized within the ESOP framework or transferred back to Ono Pharmaceutical free of charge for disposal by resolution of the board. Any surplus funds beyond trust expenses will be donated to unrelated charitable organizations upon termination of the trust.
AI-translated content. 🟢 Confidence: High See terms • Original filing